Anders Wilder Erickson

Anders Wilder Erickson

Auto-generated profile, based on publicly available information

Anders Wilder Erickson

The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in Nature
Verified
Journal Article
Closed access
PDF file
LHLiam Hendrikse
Liam Hendrikse
PHParthiv Haldipur
Parthiv Haldipur
OSOlivier Saulnier
Olivier Saulnier
JMJake Millman
Jake Millman
ASAlexandria H. Sjoboen
Alexandria H. Sjoboen
MTMichael D. Taylor
Michael D. Taylor

2 March 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AEAnders W. Erickson
Anders W. Erickson
PBPriscilla K. Brastianos
Priscilla K. Brastianos
SDSunit Das
Sunit Das
Brain metastases, or intracranial metastatic disease (IMD), are a serious and common complication of cancer, occurring in 20% of patients with primary disease.1 Patients with IMD have a 2-year survival rate of 8.1% and are likely to experience decreases in quality of life from neurologic symptoms associated with their disease or treatment.2,3 Interest exists in new therapeutic modalities for patients with IMD because of the limitations of available options, such as surgical resection and stereotactic radiosurgery, which are often reserved for patients with good performance status and low tumor burden, or whole-brain radiotherapy, which is associated with neurocognitive decline.4,5 Targeted therapies have been proposed to fill this gap, despite historical concerns that the benefit of systemic therapies as treatments for IMD has been limited by their inability to penetrate the blood-brain barrier (BBB). The National Comprehensive Cancer Network6 includes 2 targeted therapies in their most recent IMD treatment guidelines, but the Congress of Neurological Surgeons7 cites insufficient evidence to recommend the use of targeted therapies in IMD.

1 January 2020 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
AEAnders W Erickson
Anders W Erickson
FGFarinaz Ghodrati
Farinaz Ghodrati
SHSteven Habbous
Steven Habbous
KJKatarzyna Jerzak
Katarzyna Jerzak
ASArjun Sahgal
Arjun Sahgal
SDSunit Das
Sunit Das
Background: Intracranial metastatic disease (IMD) is a serious and known complication of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The role of targeted therapy for patients with HER2-positive breast cancer and IMD remains unclear. In this study, we sought to evaluate the effect of HER2-targeted therapy on IMD from HER2-positive breast cancer.Methods: We searched MEDLINE, EMBASE, CENTRAL, and gray literature sources for interventional and observational studies reporting survival, response, and safety outcomes for patients with IMD receiving HER2-targeted therapy. We pooled outcomes through meta-analysis and examined confounder effects through forest plot stratification and meta-regression. Evidence quality was evaluated using GRADE (PROSPERO CRD42020161209).Results: A total of 97 studies (37 interventional and 60 observational) were included. HER2-targeted therapy was associated with prolonged overall survival (hazard ratio [HR] 0.47; 95% confidence interval [CI], 0.39–0.56) without significantly prolonged progression-free survival (HR 0.52; 95% CI, 0.27–1.02) versus non-targeted therapy; the intracranial objective response rate was 19% (95% CI, 12–27%), intracranial disease control rate 62% (95% CI, 55–69%), intracranial complete response rate 0% (95% CI, 0–0.01%), and grade 3+ adverse event rate 26% (95% CI, 11–45%). Risk of bias was high in 40% (39/97) of studies.Conclusion: These findings support a potential role for systemic HER2-targeted therapy in the treatment of patients with IMD from HER2-positive metastatic breast cancer.

3 January 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JLJohn J. Y. Lee
John J. Y. Lee
RTRan Tao
Ran Tao
ZYZhen You
Zhen You
PHParthiv Haldipur
Parthiv Haldipur
AEAnders W. Erickson
Anders W. Erickson
MTMichael D. Taylor
Michael D. Taylor
Transcription factors are frequent cancer driver genes, exhibiting noted specificity based on the precise cell of origin. We demonstrate that ZIC1 exhibits loss-of-function (LOF) somatic events in group 4 (G4) medulloblastoma through recurrent point mutations, subchromosomal deletions and mono-allelic epigenetic repression (60% of G4 medulloblastoma). In contrast, highly similar SHH medulloblastoma exhibits distinct and diametrically opposed gain-of-function mutations and copy number gains (20% of SHH medulloblastoma). Overexpression of ZIC1 suppresses the growth of group 3 medulloblastoma models, whereas it promotes the proliferation of SHH medulloblastoma precursor cells. SHH medulloblastoma ZIC1 mutants show increased activity versus wild-type ZIC1, whereas G4 medulloblastoma ZIC1 mutants exhibit LOF phenotypes. Distinct ZIC1 mutations affect cells of the rhombic lip in diametrically opposed ways, suggesting that ZIC1 is a critical developmental transcriptional regulator in both the normal and transformed rhombic lip and identifying ZIC1 as an exquisitely context-dependent driver gene in medulloblastoma.

23 August 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
AEAnders W. Erickson
Anders W. Erickson
SDSunit Das
Sunit Das
Intracranial metastatic disease (IMD) is a common and severe complication of primary cancers. Current treatment options for IMD include surgical resection and radiation therapy, although there has been recent interest in targeted therapy in the management of IMD. As of yet, insufficient data exist to support the recommendation of targeted therapies in the treatment of IMD. Paradoxically, targeted therapy has been hypothesized to play a role in the development of IMD in patients with primary cancers. This is based on the observations that patients who receive targeted therapy for primary cancer experience prolonged survival, and that prolonged survival has been associated with increased incidence of IMD. Few data exist to clarify if treatment of primary cancers with targeted therapies influences IMD incidence. Here, we discuss the role of targeted therapy in IMD management, review the current literature on IMD incidence and targeted therapy use in primary cancer, and propose the need for future studies to inform physicians in choosing treatment options and counseling patients.

18 April 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AEAnders W. Erickson
Anders W. Erickson
HTHenry Tan
Henry Tan
LHLiam D. Hendrikse
Liam D. Hendrikse
JMJake Millman
Jake Millman
ZTZachary Thomson
Zachary Thomson
PHParthiv Haldipur
Parthiv Haldipur
The cerebellar ventricular zone (VZ) is the primary source of progenitors that generate cerebellar GABAergic neurons, including Purkinje cells (PCs) and interneurons (INs). This study provides detailed characterization of human cerebellar GABAergic neurogenesis using transcriptomic and histopathological analyses and reveals conserved and unique features compared to rodents. We show that the sequential progression of neurogenesis is conserved and occurs before 8 postconception weeks. Notably, PC differentiation occurs in the outer subventricular zone (SVZ), a region absent in the mouse cerebellum. Human PCs are generated during a compact two-week period before the onset of cerebral cortex histogenesis. A subset of human PCs retain proliferative marker expression weeks after leaving the VZ, another feature not observed in rodents. Human PC maturation is protracted with an extensive migration and reorganization throughout development with dendritic arborization developing in late gestation. We define a continuous transcriptional cascade of PC development from neuroepithelial cells to mature PCs. In contrast, while human interneuronal progenitors are born beginning in early fetal development, they exhibit an even more protracted differentiation across late gestation and into postnatal ages. These findings show dynamic developmental process for human cerebellar GABAergic neurons and underscore the importance of the embryonic environment, with early disruptions having potentially significant impacts.